

CHANGES TO THE COMPOSITION OF BOARD AND THE BOARD COMMITTEES

The Board of Directors ("**Board**") of Cordlife Group Limited (the "**Company**") wishes to inform that, in view of the changes to the Board following the Company's annual general meeting held on 14 May 2024, the Board has undertaken a review of the composition of the Board and the committees of the Board for compliance with the Listing Manual of the Singapore Exchange Securities Trading Limited ("**Listing Manual**") and the Code of Corporate Governance issued by the Monetary Authority of Singapore on 6 August 2018, and the Board wishes to announce the following changes to the composition of the Board and the committees of the Board:

1. Appointment of Dato' Dr. Teo as Chairman of the Board, the Chairman of the Nominating Committee and the Remuneration Committee, and a member of the Audit and Risk Committee

Dato' Dr. Teo Tong Kooi ("**Dato' Dr. Teo**") has been appointed as Chairman of the Board with effect from 23 May 2024. He is an independent and non-executive Director ("**ID**").

Dato' Dr. Teo has also been appointed as Chairman of the Nominating Committee and the Remuneration Committee and a member of the Audit and Risk Committee with effect from 23 May 2024. The Board considered Dato' Dr. Teo to be independent for the purpose of Rule 704(8) of the Listing Manual.

Dato' Dr. Teo has extensive experience in corporate advisory and investment management, holding key leadership positions in various multinational corporations and conglomerates, including public listed companies.

2. Appointment of Mr. Cai, Yong as Chairman of the Audit and Risk Committee and a member of the Nominating Committee and the Remuneration Committee

Mr. Cai, Yong ("**Mr. Cai**"), who is currently an Independent Director of the Company, has been appointed as the Chairman of the Audit and Risk Committee and a member of the Nominating Committee and the Remuneration Committee with effect from 23 May 2024. The Board considered Mr. Cai to be independent for the purpose of Rule 704(8) of the Listing Manual.

Mr. Cai has management experience in multinational corporations as well as large state-owned and private enterprises in the PRC, particularly in financial management, risk management and project management.

3. Appointment of Dr. Xu, Tianhong as a member of the Nominating Committee and Remuneration Committee

Dr. Xu, Tianhong, who is currently an Independent Director of the Company, has been appointed as a member of the Nominating Committee and Remuneration Committee with effect from 23 May 2024.

4. **Appointment of Ms. Chen Xiaoling as a member of the Nominating Committee**

Ms. Chen Xiaoling (“**Ms Chen**”), who is currently a Non-Independent Non-Executive Director of the Company, has been appointed as a member of the Nominating Committee with effect from 23 May 2024.

Ms Chen continues to serve as a member of the Remuneration Committee.

5. **Appointment of Mr. Yiu Ming Yiu as a member of the Nominating Committee**

Mr. Yiu Ming Yiu (“**Mr Yiu**”), who is currently a Non-Independent Non-Executive Director of the Company, has been appointed as a member of the Nominating Committee with effect from 23 May 2024.

Mr Yiu continues to serve as a member of the Audit and Risk Committee.

6. **Mr. Zhai Lingyun will relinquish his role as a member of the Nominating Committee**

Mr. Zhai Lingyun (“**Mr Zhai**”), who is currently a Non-Independent Non-Executive Director of the Company, has relinquished his role as a member of the Nominating Committee with effect from 23 May 2024. Mr Zhai who is currently a Non-Independent Non-Executive Director of the Company, decided to relinquish his role as a member of the Nominating Committee with effect from 23 May 2024, to facilitate gradual renewal and introduce fresh perspectives on the Nominating Committee.

Despite this transition, Mr. Zhai continues to serve as a Non-Independent Non-Executive Director of the Company.

7. **Composition of Board and Board Committees**

With the above changes, the re-constituted Board and Board Committees with effect from 23 May 2024 are as follows:

Board of Directors

Dato’ Dr. Teo	-	Chairman, ID
Mr. Zhai Lingyun	-	Non-Independent Non-Executive Director (“ NINED ”)
Ms. Chen Xiaoling	-	NINED
Mr. Yiu Ming Yiu	-	NINED
Mr. Chow Wai Leong	-	NINED
Mr. Cai, Yong	-	ID
Dr. Xu, Tianhong	-	ID

Audit and Risk Committee

Mr. Cai, Yong	-	Chairman / ID
Mr. Yiu Ming Yiu	-	Member / NINED
Dato’ Dr. Teo	-	Member / ID

Nominating Committee

Dato' Dr. Teo	-	Chairman / ID
Ms. Chen Xiaoling	-	Member / NINED
Mr. Yiu Ming Yiu	-	Member / NINED
Mr. Cai, Yong	-	Member / ID
Dr. Xu, Tianhong	-	Member / ID

Remuneration Committee

Dato' Dr. Teo	-	Chairman / ID
Ms. Chen Xiaoling	-	Member / NINED
Mr. Chow Wai Leong	-	Member / NINED
Dr. Xu, Tianhong	-	Member / ID
Mr. Cai, Yong	-	Member / ID

In addition, as alluded to previously, the Nominating Committee and the Board are in the process of searching for additional directors to be appointed to the Board to strengthen the capabilities and presence of the Board. This includes appointing a medical practitioner and a lawyer based and qualified in Singapore.

By order of the Board

CORDLIFE GROUP LIMITED

Sharon Lim Siew Choo
Goh Xun Er
Company Secretaries

24 May 2024